Breaking News Instant updates and real-time market news.

MCD

McDonald's

$120.38

-0.505 (-0.42%)

, WEN

Wendy's

$12.94

-0.05 (-0.38%)

12:21
11/29/16
11/29
12:21
11/29/16
12:21

McDonald's adds 75 new locations to fresh beef trial, Business Insider says

McDonald's (MCD) is expanding its experiment of offering fresh beef patties in certain restaurants with 75 new locations in Northeast Oklahoma offering fresh, not frozen, beef, reports Business Insider, citing a statement made by McDonald's Chef Chad Schafer. The experiment takes aim at rival fast food chain Wendy's (WEN), which uses fresh beef as a main selling point, Business Insider adds. Reference Link

MCD

McDonald's

$120.38

-0.505 (-0.42%)

WEN

Wendy's

$12.94

-0.05 (-0.38%)

  • 29

    Nov

MCD McDonald's
$120.38

-0.505 (-0.42%)

10/24/16
UBSW
10/24/16
NO CHANGE
Target $130
UBSW
Buy
McDonald's strategic initiatives on track, could unlock value, says UBS
UBS analyst Dennis Geiger said the strategic initiatives at McDonald's remains on track across re-franchising, repurchase, and G&A savings. The analyst believes the ongoing efficiency efforts could drive upside over time. Geiger did note that challenging comps and industry trends are making him more cautious and providing near-term challenges, leading him to lower his price target. Geiger maintained his Buy rating and lowered his price target to $130 from $137 on McDonald's shares.
10/26/16
JPMS
10/26/16
NO CHANGE
Target $425
JPMS
Overweight
Chipotle shares should be bought closer to $375, says JPMorgan
JPMorgan analyst John Ivankoe, who has a "marginal" Overweight rating on the name, believes risk tolerant investors should buy shares of Chipotle Mexican Grill closer to $375. The analyst prefers shares of Starbucks (SBUX), McDonald's (MCD) and Yum! Brands (YUM) in large cap restaurants. In a research note following Chipotle's Q3 results, Ivankoe says the company is "finally doing the things that other restaurant companies would have long done to maximize brand value." He thinks capacity enhancements could help Chipotle's comps but thinks lower stock prices are a better entry point. The stock in pre-market trading is down 4% to $388.31.
11/21/16
JPMS
11/21/16
NO CHANGE
Target $127
JPMS
Overweight
McDonald's removed from Analyst Focus List at JPMorgan
JPMorgan analyst John Ivankoe removed McDonald's from his firm's Analyst Focus List citing a less positive stance on the shares following the company's event in Australia. The analyst believes share upside is becoming more limited. He keeps an Overweight rating on McDonald's with a $127 price target.
11/29/16
FBCO
11/29/16
NO CHANGE
FBCO
Outperform
McDonald's removed from Focus List at Credit Suisse
Credit Suisse analyst Jason West removed McDonald's from the Focus List citing higher valuation, limited near-term catalysts, and limited benefits from Trump's stated goals to lower corporate/consumer taxes. West rates McDonald's an Outperform with a $128 price target.
WEN Wendy's
$12.94

-0.05 (-0.38%)

11/10/16
RHCO
11/10/16
NO CHANGE
RHCO
Wendy's gaining significant market share, says SunTrust
After Wendy's reported higher than expected Q3 EPS and same-store sales, SunTrust analyst Jake Bartlett says that the company "is taking significant market share" due to its traffic gains. The analyst keeps a $13 price target and a Buy rating on the shares.
11/25/16
ARGS
11/25/16
UPGRADE
Target $15
ARGS
Buy
Wendy's upgraded to Buy from Hold at Argus
Argus analyst John Staszak upgraded Wendy's to Buy with a $15 price target saying the company has revitalized its brand over the last three years by selling more than 800 company-owned restaurants. The sale of these restaurants has boasted free cash flow as franchisees are responsible for most capital expenditures and sale proceeds are providing capital for share buybacks and dividend increases, the analyst wrote. Staszak said by year end, franchisees will own 95% of all Wendy's restaurants and only 5% will be company-owned. The company and franchisees have remodeled 30% of restaurants, which are generating significantly greater revenue than older locations, Staszak said.
11/28/16
GSCO
11/28/16
DOWNGRADE
GSCO
Neutral
Wendy's downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Karen Holthouse downgraded Wendy's to Neutral citing valuation with the stock up 23% over the past month. The analyst views the current risk/reward as balanced and keeps a $12.50 price target for the shares.
11/29/16
11/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
On The Fly: Top five analyst downgrades: 1. Wendy's (WEN) downgraded to Neutral from Buy at Goldman with analyst Karen Holthouse citing valuation with the stock up 23% over the past month. 2. SAIC (SAIC) downgraded to Neutral from Buy at Citi with analyst Jonathan Raviv citing the recent rally in the shares and some overhang from the pending contract transition. 3. BioMarin (BMRN), Johnson & Johnson (JNJ), and Vertex (VRTX) were downgraded to Equal Weight from Overweight at Barclays. 4. Nivalis Therapeutics (NVLS) downgraded to Market Perform Raymond James, to Hold from Buy at Stifel, to Market Perform from Outperform at Cowen, and to Neutral from Outperform at Baird. 5. U.S. Steel (X) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

MIK

Michaels

$24.31

0.34 (1.42%)

07:08
12/06/16
12/06
07:08
12/06/16
07:08
Earnings
Michaels reports Q3 adjusted EPS 40c, consensus 43c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

IMMU

Immunomedics

$3.28

0.04 (1.23%)

07:08
12/06/16
12/06
07:08
12/06/16
07:08
Hot Stocks
Immunomedics introduces new ADC at ASH 2016 »

Immunomedics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

  • 16

    Feb

SAGE

SAGE Therapeutics

$51.82

2.8 (5.71%)

07:07
12/06/16
12/06
07:07
12/06/16
07:07
Hot Stocks
SAGE Therapeutics announces expedited SAGE-547 development in PPD treatment »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

SCSS

Select Comfort

$22.96

0.64 (2.87%)

07:07
12/06/16
12/06
07:07
12/06/16
07:07
Downgrade
Select Comfort rating change  »

Select Comfort downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIK

Michaels

$24.31

0.34 (1.42%)

07:07
12/06/16
12/06
07:07
12/06/16
07:07
Hot Stocks
Michaels announces increase of share repurchase program by $300M »

In December 2016, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFG

Principal Financial

$59.47

1.69 (2.92%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Conference/Events
Principal Financial to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SPPI

Spectrum

$4.03

0.03 (0.75%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Hot Stocks
Spectrum highlights survival advantage in case match control analysis of PROPEL »

Spectrum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 11

    Dec

PLUG

Plug Power

$1.47

0.04 (2.80%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Initiation
Plug Power initiated  »

Plug Power initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PSTI

Pluristem

$1.55

0.08 (5.44%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Hot Stocks
Pluristem PLX-R18 advances into second cohort of study for ARS »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPP

Green Plains Partners

$17.85

-0.15 (-0.83%)

07:06
12/06/16
12/06
07:06
12/06/16
07:06
Upgrade
Green Plains Partners rating change  »

Green Plains Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$25.82

-0.07 (-0.27%)

07:05
12/06/16
12/06
07:05
12/06/16
07:05
Hot Stocks
AstraZeneca says data presented shows TAGRISSO superiority over chemotherapy »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 16

    Feb

EARS

Auris Medical

07:05
12/06/16
12/06
07:05
12/06/16
07:05
Hot Stocks
Auris Medical on track to resume enrollment of Keyzilen Phase 3 trial »

Auris Medical Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Earnings
Synchronoss sees FY17 pro forma EPS $2.45-$2.60 for combined entity »

May not compare to…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

CHTR

Charter

$270.93

4.26 (1.60%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Initiation
Charter initiated  »

Charter initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MDGN

Medgenics

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Initiation
Medgenics initiated  »

Medgenics initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AM

Antero Midstream

$28.48

-0.1 (-0.35%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Upgrade
Antero Midstream rating change  »

Antero Midstream upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$39.86

0.17 (0.43%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Upgrade
HSBC rating change  »

HSBC upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGTX

TG Therapeutics

$5.70

0.2 (3.64%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
TG Therapeutics GENUINE Phase 3 study reaches target enrollment »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
Synchronoss to divest part of activation business to Sequential for $146M »

Synchronoss is also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
Synchronoss to acquire Intralinks for $13/share, or $821M in equity value »

Synchronoss Technologies…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

TEVA

Teva

$37.04

0.51 (1.40%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Recommendations
Teva analyst commentary  »

Wells views departure of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

NVCN

Neovasc

$1.42

0.56 (65.12%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Hot Stocks
Neovasc provides update on Tiara transcatheter mitral valve »

Neovasc provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$9.93

-0.07 (-0.70%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Initiation
GDS Holdings initiated  »

GDS Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Hot Stocks
Breaking Hot Stocks news story on Synchronoss, Intralinks »

Synchronoss to acquire…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

KKR

KKR

$15.67

0.19 (1.23%)

, BX

Blackstone

$26.40

0.54 (2.09%)

07:01
12/06/16
12/06
07:01
12/06/16
07:01
Hot Stocks
KKR to acquire Optiv Security from investors, including fund managed by Blackstone »

Optiv Security, a…

KKR

KKR

$15.67

0.19 (1.23%)

BX

Blackstone

$26.40

0.54 (2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.